CA3107169A1 - Pharmaceutical dosage form which can be administered orally and has modified release - Google Patents
Pharmaceutical dosage form which can be administered orally and has modified release Download PDFInfo
- Publication number
- CA3107169A1 CA3107169A1 CA3107169A CA3107169A CA3107169A1 CA 3107169 A1 CA3107169 A1 CA 3107169A1 CA 3107169 A CA3107169 A CA 3107169A CA 3107169 A CA3107169 A CA 3107169A CA 3107169 A1 CA3107169 A1 CA 3107169A1
- Authority
- CA
- Canada
- Prior art keywords
- disorders
- compound
- formula
- weight
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185127.0 | 2018-07-24 | ||
| US16/043,567 US10905667B2 (en) | 2018-07-24 | 2018-07-24 | Orally administrable modified-release pharmaceutical dosage form |
| US16/043,567 | 2018-07-24 | ||
| EP18185127 | 2018-07-24 | ||
| PCT/EP2019/069561 WO2020020789A1 (de) | 2018-07-24 | 2019-07-19 | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3107169A1 true CA3107169A1 (en) | 2020-01-30 |
Family
ID=67314781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3107169A Pending CA3107169A1 (en) | 2018-07-24 | 2019-07-19 | Pharmaceutical dosage form which can be administered orally and has modified release |
Country Status (22)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202112359A (zh) | 2019-06-07 | 2021-04-01 | 德商拜耳廠股份有限公司 | sGC活化劑於治療眼科疾病之用途 |
| CN112557533A (zh) * | 2020-11-29 | 2021-03-26 | 北京康立生医药技术开发有限公司 | 一种恩格列净的分析方法 |
| EP4339184B1 (en) * | 2021-05-14 | 2026-08-12 | Medshine Discovery Inc. | Alkyl carboxylic acid compounds and application thereof |
| CN119300815A (zh) | 2022-06-09 | 2025-01-10 | 拜耳公司 | 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂 |
| CN117982443B (zh) * | 2022-10-31 | 2026-03-06 | 优辉药业(北京)有限公司 | 一种达格列净二甲双胍缓释片剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
| DE3868077D1 (de) | 1987-01-14 | 1992-03-12 | Ciba Geigy Ag | Therapeutisches system fuer schwerloesliche wirkstoffe. |
| DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2590979A1 (de) | 2010-07-09 | 2013-05-15 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) * | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
| PE20211391A1 (es) | 2017-12-01 | 2021-07-27 | Bayer Pharma AG | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico |
-
2019
- 2019-07-19 TW TW108125542A patent/TW202019402A/zh unknown
- 2019-07-19 UY UY0001038308A patent/UY38308A/es not_active Application Discontinuation
- 2019-07-19 MA MA053368A patent/MA53368A/fr unknown
- 2019-07-19 CR CR20210043A patent/CR20210043A/es unknown
- 2019-07-19 SG SG11202100369WA patent/SG11202100369WA/en unknown
- 2019-07-19 EP EP19740580.6A patent/EP3826627B1/de active Active
- 2019-07-19 MX MX2021000904A patent/MX2021000904A/es unknown
- 2019-07-19 CN CN201980049223.8A patent/CN112469402B/zh not_active Expired - Fee Related
- 2019-07-19 WO PCT/EP2019/069561 patent/WO2020020789A1/de not_active Ceased
- 2019-07-19 JO JOP/2021/0019A patent/JOP20210019A1/ar unknown
- 2019-07-19 JP JP2021503578A patent/JP2021532113A/ja active Pending
- 2019-07-19 BR BR112020026644-2A patent/BR112020026644A2/pt not_active Application Discontinuation
- 2019-07-19 PE PE2021000084A patent/PE20210415A1/es unknown
- 2019-07-19 AU AU2019311234A patent/AU2019311234A1/en not_active Abandoned
- 2019-07-19 CA CA3107169A patent/CA3107169A1/en active Pending
- 2019-07-19 KR KR1020217004994A patent/KR20210035235A/ko not_active Withdrawn
-
2021
- 2021-01-11 IL IL280083A patent/IL280083A/en unknown
- 2021-01-18 EC ECSENADI20213707A patent/ECSP21003707A/es unknown
- 2021-01-19 CO CONC2021/0000450A patent/CO2021000450A2/es unknown
- 2021-01-20 CL CL2021000160A patent/CL2021000160A1/es unknown
- 2021-01-20 DO DO2021000015A patent/DOP2021000015A/es unknown
- 2021-01-22 PH PH12021550170A patent/PH12021550170A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020020789A1 (de) | 2020-01-30 |
| SG11202100369WA (en) | 2021-02-25 |
| EP3826627B1 (de) | 2023-10-18 |
| PE20210415A1 (es) | 2021-03-04 |
| CO2021000450A2 (es) | 2021-01-29 |
| PH12021550170A1 (en) | 2021-09-13 |
| TW202019402A (zh) | 2020-06-01 |
| JOP20210019A1 (ar) | 2021-01-24 |
| MA53368A (fr) | 2021-06-02 |
| MX2021000904A (es) | 2021-03-31 |
| CN112469402B (zh) | 2024-05-14 |
| KR20210035235A (ko) | 2021-03-31 |
| IL280083A (en) | 2021-03-01 |
| CL2021000160A1 (es) | 2021-06-04 |
| UY38308A (es) | 2020-02-28 |
| ECSP21003707A (es) | 2021-02-26 |
| EP3826627A1 (de) | 2021-06-02 |
| CR20210043A (es) | 2021-03-09 |
| BR112020026644A2 (pt) | 2021-03-23 |
| CN112469402A (zh) | 2021-03-09 |
| AU2019311234A1 (en) | 2021-02-04 |
| JP2021532113A (ja) | 2021-11-25 |
| DOP2021000015A (es) | 2021-02-15 |
| EP3826627C0 (de) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220257547A1 (en) | Orally administrable modified-release pharmaceutical dosage form | |
| CN112469402B (zh) | 可口服给药且缓释的药物剂型 | |
| US10662188B2 (en) | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | |
| US20200237648A1 (en) | Orally administrable modified-released pharmaceutical dosage form | |
| EP4049660B1 (en) | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | |
| JP2012522058A (ja) | 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンii受容体アゴニストの経口製剤 | |
| WO2003082805A1 (en) | Low water-soluble venlafaxine salts | |
| TW201932462A (zh) | 經取代的咪唑并吡啶醯胺類及其用途 | |
| AU2021393988A9 (en) | Substituted pyrazolo piperidine carboxylic acids | |
| US20210283046A1 (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
| HUE033496T2 (en) | New sitagliptin sulfate crystal form | |
| JP2025518350A (ja) | 女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター | |
| CN101068550B (zh) | 含有释放速度控制组分的羧酰胺人类免疫缺陷整合酶抑制剂药物制剂 | |
| CN104582684A (zh) | 包含5-氯-n-({(5s)-2-氧代-3-[4-(3-氧代-4-吗啉基)苯基]-1,3-噁唑烷-5-基}甲基)-2-噻吩甲酰胺的药物剂型 | |
| WO2022112213A1 (en) | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide | |
| EP2293792A1 (en) | Diaryl ureas for treating heart failure | |
| HK40041248A (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
| HK40041640A (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
| WO2018153900A1 (de) | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern | |
| WO2018153897A1 (de) | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern | |
| EA042489B1 (ru) | Фармацевтическая композиция, включающая сакубитрил и валсартан |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260129 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260330 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260513 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |